microRNA News and Research RSS Feed - microRNA News and Research

In genetics, microRNAs (miRNA) are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.
Sciatic nerve injury can cause differential expression of microRNAs in dorsal root ganglia

Sciatic nerve injury can cause differential expression of microRNAs in dorsal root ganglia

Slit-Robo GTPase-activating protein 3 contains a Rho GAP domain that regulates the activities of Rho family GTPases and affects actin polymerization, which influences dendrite elaboration, neurite outgrowth and axon guidance, contributing to neural regeneration. [More]
Researchers identify new biomarker that predicts effectiveness of glioblastoma treatment

Researchers identify new biomarker that predicts effectiveness of glioblastoma treatment

Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma - the most common form of primary brain cancer - will respond to chemotherapy. The findings are published in the July print issue of Oncotarget. [More]
Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results. [More]
Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

According the World Health Organization, such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease. That is why numerous scientists around the world have invested a great deal of effort in understanding these diseases. Yet the molecular and cellular mechanisms that underlie these problems are still only partly understood. [More]
GENETICS and G3: Genes|Genomes|Genetics publish special collection on genetics of immunity

GENETICS and G3: Genes|Genomes|Genetics publish special collection on genetics of immunity

Immunity is what stops you dying from a common cold or a tiny pinprick. Differences in resistance or tolerance to disease influence who catches the bug that's going around the office, or which species succumb to the deadly fungus devastating frogs around the world. [More]
Researchers identify muscle-building mechanism that could be important in addressing sarcopenia

Researchers identify muscle-building mechanism that could be important in addressing sarcopenia

Sarcopenia - the significant loss of muscle mass and function that can occur as we age - is associated with many chronic conditions such as diabetes, high cholesterol and obesity. [More]
Study show good compliance and patient survival outcomes using LDCT screening protocol

Study show good compliance and patient survival outcomes using LDCT screening protocol

Investigators of the COSMOS (Continuous Observation of SMOking Subjects) study show good compliance and patient survival outcomes using a 5-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer. [More]
Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology. [More]
Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Improved diagnosis and management of one of the most common cancers in men - prostate cancer - could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease. [More]
Tiny molecule may provide marker for depression

Tiny molecule may provide marker for depression

Levels of a small molecule found only in humans and in other primates are lower in the brains of depressed individuals, according to researchers at McGill University and the Douglas Institute. [More]
Norgen launches 6 novel kits for simple isolation of NA from blood, plasma, serum, urine

Norgen launches 6 novel kits for simple isolation of NA from blood, plasma, serum, urine

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 6 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA. [More]
Frost & Sullivan: Western European NGS market estimated to reach $697.3M in 2018

Frost & Sullivan: Western European NGS market estimated to reach $697.3M in 2018

The Western European next-generation sequencing (NGS) market is poised for steady growth, owing to the emergence of new applications such as non-invasive prenatal testing and comprehensive oncology panels. [More]
Researcher identify four new microRNAs involved in regulation of BDNF levels

Researcher identify four new microRNAs involved in regulation of BDNF levels

Brain Derived Neurotrophic Factor (BDNF) regulates many processes including memory and learning in our daily tasks. [More]
Newly discovered molecule provides drug target for controlling both asthma and cancerous tumor growth

Newly discovered molecule provides drug target for controlling both asthma and cancerous tumor growth

A newly discovered molecule provides a new drug target for controlling both asthma-induced muscle thickening and cancerous tumor growth. This molecule, called "microRNA-10a," normally helps genes produce proteins or make copies of themselves, also play an important role in the growth or overgrowth of human airway smooth muscle cells and some forms of cancer. [More]
Exposure to microgravity can simulate aging for immune cells

Exposure to microgravity can simulate aging for immune cells

Telling someone to "act your age" is another way of asking him or her to behave better. Age, however, does not always bring improvements. [More]
Researchers uncover novel function of Amyloid Precursor Protein linked to Alzheimer's disease

Researchers uncover novel function of Amyloid Precursor Protein linked to Alzheimer's disease

A research team led by the National Neuroscience Institute has uncovered a novel function of the Amyloid Precursor Protein (APP), one of the main pathogenic culprits of Alzheimer's disease. This discovery may help researchers understand how the protein goes awry in the brains of Alzheimer's disease patients, and potentially paves the way for the development of innovative therapeutics to improve the brain function of dementia patients. [More]
Small gene embedded in large gene contributes to development of acute myeloid leukemia

Small gene embedded in large gene contributes to development of acute myeloid leukemia

A small gene that is embedded in a larger, well-known gene is the true leukemia-promoting force usually attributed to the larger gene, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). [More]
U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

University of Virginia neurologist Dr. Erin Pennock Foff, biologist Sarah Kucenas and biomedical engineer Shayn Peirce-Cotter have been named recipients of 2013 Hartwell Individual Biomedical Research Awards to benefit children of the United States. Each scientist will receive $100,000 in direct annual research support from The Hartwell Foundation for three years. [More]